{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107320","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.948888+00:00","generated_at":"2026-05-17T14:44:49.113659+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials","bullets":["ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.","ARD-201 attenuated weight regain after tirzepatide withdrawal; combo with low-dose tirzepatide outperformed high-dose tirzepatide alone.","Phase 2 POWER trial (2H 2025) targets weight regain prevention in patients discontinuing GLP-1RA therapy.","Phase 2 STRENGTH trial (1H 2026) to test monotherapy and combination with GLP-1RA, replacing prior EMPOWER trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107320","json":"https://secwatch.observer/filing/0000950170-25-107320.json","markdown":"https://secwatch.observer/filing/0000950170-25-107320.md","text":"https://secwatch.observer/filing/0000950170-25-107320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/0000950170-25-107320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/ck0001774857-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:44:49.113659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}